News

Press Releases

Edgewise Therapeutics Completes $95 Million Series C Financing to Advance Clinical Development of Muscular Dystrophy Program

December 8, 2020 -
Edgewise Therapeutics, a clinical-stage biopharmaceutical company developing orally bioavailable, small molecule therapies for musculoskeletal diseases, today announced the closing of a $95 million Series C preferred stock financing led by Viking Global Investors.
Learn More »

Edgewise Therapeutics Initiates Phase 1 Clinical Trial of EDG-5506 in Becker Muscular Dystrophy

November 11, 2020 -
Edgewise Therapeutics, a clinical-stage biopharmaceutical company developing small molecule therapies for musculoskeletal diseases, today announced the initiation of a Phase 1 clinical trial of EDG-5506.
Learn More »

Edgewise Therapeutics Appoints John Moore as General Counsel

October 29, 2020 -
Edgewise Therapeutics, a clinical-stage biopharmaceutical company developing small molecule therapies for musculoskeletal diseases, today announced the appointment of John Moore to the newly created position of General Counsel.
Learn More »

Edgewise Therapeutics Appoints Behrad Derakhshan as Chief Business Officer

October 22, 2020 -
Edgewise Therapeutics, a clinical-stage biopharmaceutical company developing small molecule therapies for musculoskeletal diseases, today announced the appointment of Behrad Derakhshan, Ph.D., to the newly created position of Chief Business Officer.
Learn More »

Edgewise Therapeutics Appoints Michael Carruthers as Chief Financial Officer

October 16, 2020 -
Edgewise Therapeutics, a clinical-stage biopharmaceutical company developing small molecule therapies for musculoskeletal diseases, today announced the appointment of R. Michael Carruthers to the newly created position of Chief Financial Officer (CFO).
Learn More »

Edgewise Therapeutics Appoints Abby H. Bronson, M.B.A., as Vice President, Patient Advocacy and External Innovation

July 8, 2020 -
Edgewise Therapeutics, a biopharmaceutical company developing small molecule therapies for musculoskeletal diseases, today announced the appointment of Abby H. Bronson to the newly created position of Vice President, Patient Advocacy and External Innovation. Ms. Bronson will be responsible for leading patient advocacy and building key external relationships with the muscular dystrophy community with the goal of bringing patient insights into drug development.
Learn More »

Edgewise Therapeutics Appoints Kirsten L. Gruis, M.D., M.S. as Chief Medical Officer

June 17, 2020 -
Edgewise Therapeutics, a biopharmaceutical company developing small molecule therapies for musculoskeletal diseases, today announced the appointment of Kirsten L. Gruis, M.D., M.S. to the newly created position of Chief Medical Officer. Dr. Gruis will be responsible for leading clinical, medical and regulatory strategy and operations for the drug pipeline, including EDG-5506, the company’s lead product candidate that is being prepared for clinical development for Duchenne and Becker muscular dystrophy (DMD and BMD).
Learn More »

Edgewise Therapeutics Closes $50 Million Series B Financing

September 17, 2019 -
Edgewise Therapeutics, a preclinical company developing small molecule therapies for musculoskeletal diseases, has announced the closing of a $50 million Series B financing round. The round was co-led by Novo Holdings A/S and U.S. Venture Partners (USVP) and included participation from Deerfield Management, New Leaf Venture Partners, and Cure Duchenne Ventures, as well as existing founding investor OrbiMed Advisors. The financing will support the advancement of Edgewise Therapeutic’s lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company’s pipeline. Joining the Board of Directors will be Kenneth Harrison, Ph.D., Principal at Novo Ventures and Jonathan Root, M.D., General Partner at USVP; Robert Jackson, M.D., Partner and CSO at Deerfield will join as a Board Observer.
Learn More »

Upcoming Events

Jett Foundation’s Rare Disease Day Event Celebration

Date: February 26, 2021

Time: 2:00 - 3:30 PM EST

Past Events

Parent Project Muscular Dystrophy Italy Community Webinar: “An introduction to Edgewise Therapeutics: Our company and our plans”

Date: February 21, 2021

Time: 6:30 AM EST

Location: Virtual

CureDuchenne Community Webinar: “An introduction to Edgewise Therapeutics: Our company and our plans”

Date: February 16, 2021

Time: 3:00 PM EST

Location: Virtual

PPMD Annual Conference 2020: “Muscle Health and Exercise”

Date: July 8, 2020

Investors

Edgewise has raised $160.5M in private financing from the following institutional investors.